GlassScriptPhysician profile
Stephanie Silverman
NPI 1679941363
$7,808.95
in general payments reported to CMS, 2019-2025
44 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,609 · 2022: $1,398 · 2023: $1,691 · 2024: $1,636 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,709 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,708.66 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.38 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $828.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $781.15 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $612.23 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $605.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $482.61 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $469.89 | 2021-2025 | Mounjaro, Kisunla, Trulicity |
| Novartis Pharmaceuticals Corporation | $404.28 | 2021-2025 | |
| Daiichi Sankyo INC. | $320.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $261.42 | 2021-2025 | Belsomra, Steglatro, Steglujan |
| Astellas Pharma US INC | $258.71 | 2022-2024 | Veozah, Myrbetriq |
| Amgen INC. | $231.58 | 2021-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.46 | 2021-2025 | Jardiance, Ofev |
| Tandem Diabetes Care, INC. | $188.27 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $130.23 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $87.94 | 2022-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $81.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.48 | 2021-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $77.63 | 2021-2022 | |
| Dynavax Technologies Corporation | $73.59 | 2023-2025 | Heplisav-B |
| Corcept Therapeutics | $67.28 | 2025 | Korlym |
| Abbott Laboratories | $65.20 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $63.21 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $58.64 | 2024-2025 | Voquezna |
| Dexcom, INC. | $53.87 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $48.41 | 2024 | Minimed 780g |
| Lundbeck LLC | $44.28 | 2024 | Vyepti |
| Stryker Corporation | $39.70 | 2025 | Clarifix |
| Eisai INC. | $32.07 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.14 | 2022 | |
| Seqirus USA INC | $24.47 | 2025 | Fluad, Flucelvax |
| Itamar Medical INC | $20.84 | 2024 | Watchpatone |
| Nevro Corp. | $19.83 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.28 | 2022 | |
| Madrigal Pharmaceuticals | $18.70 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $18.37 | 2024 | Gemtesa |
| Abiomed | $16.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2021 | |
| Radius Health, INC. | $14.54 | 2025 | Tymlos |
| Axsome Therapeutics, INC. | $14.53 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $14.32 | 2021 | |
| Esperion Therapeutics, INC. | $14.17 | 2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.